BMS-639623

BMS-639623 is a potent and orally activeCCR3 antagonist with an IC50 of 0.3 nM. BMS-639623 picomolar inhibition potency against eosinophil chemotaxis (IC50=38 pM) . BMS-639623 can be used for the research of asthma[1].

Product Specifications

CAS Number

[675122-44-8]

UNSPSC

12352005

Target

CCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bms-639623.html

Solubility

10 mM in DMSO

Smiles

O=C(NC1=CC=CC(C2=NN=NN2C)=C1)N[C@H](C)[C@@H](O)CN3C[C@H](CC4=CC=C(F)C=C4)CCC3

Molecular Formula

C25H32FN7O2

Molecular Weight

481.57

References & Citations

[1]Santella JB 3rd, et al. From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis. Bioorg Med Chem Lett. 2008;18 (2) :576-585.